Pharma news
Americas
Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid. 17 January 2022
Pharma
Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements. 13 January 2022
Pharma
Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment. 13 January 2022
Pharma
Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board that it should not institute inter partes reviews of a patent covering Actemra, a treatment for arthritis under the NHK/Fintiv rule. 11 January 2022
Americas
A former Monsanto employee has pled guilty to conspiring to steal trade secrets from the biotech company in order to share the information with the Chinese government. 10 January 2022
Americas
Sarepta Therapeutics won’t be able to rely on a “safe harbour” provision to protect its gene therapy invention from a patent infringement suit from biotech Regenxbio and the University of Pennsylvania, a Delaware court has ruled. 6 January 2022
Pharma
Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice. 4 January 2022
Americas
Novartis Pharmaceuticals has prevailed against China’s HEC Pharm at the US Court of Appeals for the Federal Circuit, after a majority panel of judges held that a patent covering the multiple sclerosis drug Gilenya was valid. 4 January 2022
Pharma
Oxfam America has filed a complaint with the US Securities and Exchange Commission (SEC) claiming that Moderna failed to inform investors that it was in a dispute with the National Institutes of Health over a COVID–19 vaccine patent. 23 December 2021
Pharma
Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson. 22 December 2021